Journal article
An introduction to the Marburg virus vaccine consortium, MARVAC
- Abstract:
- Marburg Virus Disease (MVD) is a lethal single-stranded RNA virus transmitted by Egyptian rousette bats, causing 12 surges in Sub-Saharan Africa, including a recent outbreak in Tanzania in 2023. With a fatality rate of approximately 90%, no approved vaccines currently exist. Ongoing research explores potential candidates, such as a recombinant vesicular stomatitis virus (VSV)-based vaccine and MVA-BN-Filo, aiming to combat this deadly infection. The objective of this review is to comprehensively examine Marburg virus vaccines, exploring various candidates and their development stages, efficacy in non-human primates and human studies, and challenges faced in the development process. Various vaccines are under development, including Ad26, Ad5, viral vector, and DNA vaccines. Promising candidates like Ad26.Filo and ChAd3-MARV have emerged. Additionally, VLP-based, DNA plasmid and rVSV-based vaccines are discussed, highlighting their effectiveness and challenges in development, such as limited information, gene expression issues, and outbreak control measures. The implications for future research and clinical practice/policy development are significant. Marburg virus vaccine development shows promise in mitigating the threat posed by this deadly pathogen. Despite complex challenges, advancements in vaccine candidates offer hope. Continued research and development may lead to the successful prevention of major Marburg virus outbreaks. Ongoing clinical trials indicate potential breakthroughs in a short period, contributing to public health protection.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 525.0KB, Terms of use)
-
- Publisher copy:
- 10.1371/journal.ppat.1010805
Authors
+ Biomedical Advanced Research and Development Authority
More from this funder
- Funder identifier:
- 10.13039/100012399
- Grant:
- 75A50119C00055
+ National Institute of Allergy and Infectious Diseases, NIH
More from this funder
- Funder identifier:
- 10.13039/100000060
- Grant:
- U19AI142785
+ Division of Intramural Research, National Institute of Allergy and Infectious Diseases
More from this funder
- Funder identifier:
- 10.13039/100006492
- Publisher:
- Public Library of Science
- Journal:
- PLoS Pathogens More from this journal
- Volume:
- 18
- Issue:
- 10
- Pages:
- e1010805-e1010805
- Publication date:
- 2022-10-13
- DOI:
- EISSN:
-
1553-7374
- ISSN:
-
1553-7366
- Language:
-
English
- Keywords:
- Pubs id:
-
1286193
- Local pid:
-
pubs:1286193
- Source identifiers:
-
W4305071856
- Deposit date:
-
2026-04-29
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2022
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record